Policy / Alpha Vantage News Sentiment

GSK ends brain drug alliance with Alector

GSK has terminated its collaboration with biotechnology company Alector for neurodegenerative disease drugs, following clinical setbacks for both experimental medicines. The original $2.2 billion deal, which marked GSK's return to neuroscience, saw its value decrease after one drug failed to significantly slow disease progression and another's trial was discontinued. This marks Alector's second major partnership to fail, leading to significant stock value loss and layoffs.